Therapeutic ultrasound (TUS) is a promising non-viral clinical approach for the delivery of genes. This study demonstrates the efficient delivery and localization of DNA in subcutaneous tumors facilitated by TUS application and examines the contribution of ultrasound contrast-agent (USCA) addition on transfection. The study addresses the importance of in vivo optimization when using long-term TUS and USCA based on data achieved in vitro. In vitro results showed that transfection of TrampC2 prostate cancer (Pca) cells using genes encoding for luciferase and green fluorescent protein was enhanced when DNA and Optison were added together and TUS was applied for 20 or 30 min. In vivo results showed that the highest transfection was achieved when Optison and DNA were co-injected intratumoraly, and TUS was applied for 20 min. Using Optison significantly increased protein distribution in the tumor. However, in vivo expression level was decreased by two and four fold at 7 and 14 days, respectively, post-TUS. The study establishes the potential of intratumoral delivery of DNA-Optison, followed by TUS as an effective, non-toxic, gene delivery method that could provide a safe, clinical alternative to current viral gene delivery approaches where short-term gene expression is needed.
Introduction
Unlike conventional therapy, gene therapy can target the cancer cells without the use of the therapeutic itself and with less systemic side effects. However, for cancer gene therapy as for gene therapy in general, there is a need to overcome limitations associated with the type of vectors used to deliver DNA efficiently. Non-viral vectors are emerging as substitutes to the viral ones as they are considered safer, easier to prepare, lack immunogenic response and do not have a limit in the size of gene introduced. 1, 2 However, these vectors are effective in vitro but suffer from low transfection efficiency in vivo, and as with the viral ones, lack tissue specificity. 1 Ultrasound (US) is a relatively new non-viral approach used to deliver genes into cells and tissue. [3] [4] [5] [6] [7] [8] US waves can be directed to a specific tissue or organ, and can thus localize the DNA of interest and overcome one of the major problems associated with other non-viral vectors for cancer gene therapy. 9, 10 Several US modalities are used for gene therapy applications. 4, 6 A common one is diagnostic US, which operates at frequencies of 3-10 MHz and moderated intensities. 10, 11 Another US modality is high-intensity focused US (HIFU, 10-50 W/ cm 2 ), which is considered to be destructive and used mainly for ablation therapy. 9, 12, 13 Recently, a third US modality, therapeutic ultrasound (TUS), which operates at moderate frequencies of 1-3 MHz and intensities of 0.5-3 W/cm 2 , is being utilized for gene therapy. 7, 14 This TUS modality is used mainly for physiotherapy and is approved for clinical applications. 15 The mechanism attributed for US-mediated gene delivery is not fully clear, although cavitation (the creation and oscillation of gas bubbles in a liquid) is suggested to play a major role in cell membrane permeabilization.
Looking at the literature, TUS, with or without USCA, was used to deliver genes to muscles, 5, 21, 22 liver, 23 vasculature 3, 14, 24, 25 and also to tumors. 10, 13, 26 These studies have used different TUS parameters such as intensity, duty cycle (DC) and time applications, particularly focusing on short application times (less than 15 min), and also used different contrast agent or liposomes. 22 Nevertheless, in vivo optimization of all these parameters together was not addressed before, mainly when transfecting tumors. This multilevel in vivo optimization include parameters associated with the TUS itself (e.g. intensity, exposure time) as well as the ones associated with the in vivo settings, such as plasmid injection site, localization of the transfection and the duration of gene expression. Knowledge of this data is crucial to achieve successful transfection when applying TUS with a therapeutic gene.
To properly control the application of TUS in combination with USCA in vivo and to optimize the expression level and efficiency, TUS parameters need to be optimized first in vitro and then translated to the in vivo settings. Previously, we have shown that long-term TUS (20-30 min) resulted in high transfection in vitro. 7, 19 Most importantly, the long-term TUS application was found to enhance DNA trafficking to the nucleus, accelerating its expression to protein. Yet, no study has evaluated the effect and contribution of long-term TUS application with USCA, on expression level and efficiency in vivo in general, and in tumors in particular.
The present study addresses all the above issues in order to optimize the use of long-term TUS, with or without the addition of Optison, an USCA, for efficient transfection in tumors in vivo. For these studies, prostate cancer (PCa) was chosen as a tumor model as this is one of the most common types of cancer in the Western world and one of the leading causes of cancer death in the USA. 27, 28 We have addressed the following goals: (I) implementation of data obtained in vitro into the in vivo settings, (II) optimization of the addition of Optison and the route of DNA-Optison administration on tumor transfection and protein distribution in the tumor when using long-term TUS and (III) determine the duration of protein expression post-TUS transfection with and without Optison. Optimization of all these parameters is a prerequisite in bringing such technology for therapeutic clinical applications.
Materials and methods

Plasmids
Two reporter plasmids were used: pGL3-Luc (Promega, Madison, WI, USA) containing the firefly luciferase gene and pIRES-EGFP (Clontech Laboratories, Mountain View, CA, USA), which contains the gene for enhanced green florescent protein (GFP). Plasmid DNAs (pDNA) were amplified and purified using JET-Star (Genomed, Germany) according to the manufacturer's protocol and dissolved in TE buffer (10 mM Tris-HCl, 1 mM ethylenediaminetetraacetic acid). The purified plasmids were quantified using absorbance at wavelength of 260/280 nm.
Cell culture
Murine PCa cells derived from Transgenic Adenocarcinoma of mouse prostate-TRAMP-C2 (PC2, received from Professor Roni Apte BGU, Israel) were grown in Dulbecco's modified Eagle's medium (Gibco-Invitrogen Cell Culture, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS, Gibco), 5 mg/ml insulin (Biological Industries, Israel), 10 À8 M dihydrotestosterone (DHT, Sigma Aldrich, Rehovot, Israel), penicillin/streptomycin solution (Biological Industries, Israel) and fungizone (Gibco). Cells were cultured as monolayers in a humidified atmosphere of 95% air and 5% CO 2 at 371C, and used within passages 4-10.
In vitro gene transfection
In vitro gene transfection using TUS was performed as previously described. 7, 19 In brief, cells seeded in six-well plates were treated with pDNA coding for luciferase or GFP (7.5 mg/ml) and then exposed to 1 MHz TUS (UltraMax, XLTEK, Canada) at 30% DC, 2 W/cm 2 (correspond to 0.159 MPa or mechanical index (MI) 7 ) for total exposure time of 10, 20 or 30 min. Control cells received only DNA without the application of TUS, or TUS alone. The effect of USCA on cell transfection was performed using Optison, human albumin microspheres (Amersham Health, GE Healthcare, Solingen, Germany). Optison (10%), and DNA were first incubated as previously described. 19 Cells were then transfected using the same parameters as without Optison. An additional control was cells that were transfected using Lipofectamine (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. For all studies, cell viability was detected using methylthiazolyldiphenyl-tetrazolium bromide (MTT, Sigma) according to the manufacturer's protocol. Measurements of luciferase activity were performed 3 days post-TUS application according to the standard protocol (Promega) and as described. 7 Luciferase activity is reported as the mean of relative light units (RLUs) obtained from each sample divided by total protein weight measured for each sample. Cells expressing GFP were followed under fluorescent microscope (TE2000-S, Nikon, Europe Badhoevedorp, The Netherlands). Transfection efficiency was determined as the number of cells expressing GFP per total number of cells in a field and by flow cytometry (FACS Calibur, BD Biosciences, San Jose, CA, USA). 7 Kinetics of gene expression post-TUS transfection in vitro TUS was used to transfect PC2 with pGL-Luc preincubated with Optison or alone, as described above. Luciferase activity was measured during 21 days post-TUS application. In another set of experiments, total RNA was extracted from cells at 2, 3, 4, 7, 14 and 21 days post-TUS transfection and prepared for reverse transcriptase-polymerase chain reaction (RT-PCR).
RNA preparation and RT-PCR
Total RNA was extracted from transfected and nontransfected cells using Tri-Reagent (Sigma) and quantified at 260 nm. Synthesis of cDNA was performed using random primers (AB-Gene, Epsom, UK) with the firststrand cDNA used as the template for polymerase chain reaction (PCR In the first set of experiments, the effect of plasmid injection site on DNA expression level and the area of transfection in the tumor were determined by sacrificing the mice 3 days post-TUS application, and tumors, skin and livers were taken for analyses. Based on the results of the first experiment a second experiment was designed in which the duration of transfection was studied. In this experiment, DNA was injected i.t. with or without Optison. Mice were then treated with TUS and sacrificed 3, 7 or 14 days post-TUS application. For each of the above experiments, the control groups received DNA alone or DNA-Optison without the application of TUS. During in vivo transfection studies, a needle thermocouple (Omega Inc.) was placed under the tumor to measure the temperature at the flank treated with TUS.
For luciferase activity measurements, tumor, skin and liver were frozen in liquid nitrogen, digested and suspended in lyses buffer (CCLR, Promega). The lysate was centrifuged, and the supernatant was analyzed for total protein and luciferase activity as described. Expression of luciferase in the tumor was also evaluated using RT-PCR. Tumors were frozen in liquid nitrogen, digested and suspended in TRI-Reagent. RNA preparation and RT-PCR were performed as described.
When pGFP was used, tumors and skin around the tumors were harvested, embedded in OCT (Tissue-Tek), frozen in liquid nitrogen, and stored at À801C until further analyses. Frozen sections (7 mm) were cut using a cryostat (Leica) and fixed with 4% paraformaldehyde. Nuclei were stained with 4 0 ,6-diamidino-2-phenyindole (DAPI), and the sections were mounted with Fluoromount-G (EMS). GFP expression in the tumors was viewed with fluorescent microscope. For each micrograph, GFP expression and transfection efficiency were quantified in three randomly chosen fields per section in at least five sections at Â 200 using Laboratory Universal Computer Image Analyses (LUCIA, Laboratory Imaging, CZ). All animal studies were approved by the Animal Ethics Committee at the Technion (Haifa, Israel).
Histology
Histological analyses were performed on sections of 7 mm from each sample (tumor, skin or liver). The sections were stained with hematoxylin and eosin (H&E) as described. 9 Representative micrographs were taken at Â 200 and Â 400.
Statistical analysis
All data are expressed as mean value7standard error of the mean. All in vitro experiments were performed at least six times and then repeated three times at different occasions. In vivo experiments were performed on groups of five mice, and each experiment was repeated twice. All micrographs are representatives of at least 10 random micrographs taken from independent experiments. Statistical differences were determined using Student's t-test for independent samples. Statistical significance was defined as Po0.05.
Results
In vitro optimization of DNA expression level and efficiency For the in vitro optimization studies, DNA alone or with Optison was added to PC2 cells and TUS (30% DC, 2 W/ cm 2 ) was applied for different time application ( Figure 1 ). As seen, the addition of Optison during TUS application increased PC2 cell transfection significantly compared with PC2 cells treated with TUS alone (Po0.05). This increase was seen when TUS was applied for 10, 20 and 30 min. The highest transfection was achieved when TUS was applied at 30% DC, 2 W/cm 2 for 30 min. These parameters led to luciferase activity of 3.9 Â In vivo optimization of plasmid injection site To determine the effect of DNA administration site on transfection with TUS, pGL-Luc was injected i.t. or s.c. and tumors were then exposed to TUS (30% DC, 2 W/ cm 2 , 20 min, Figure 3 ). When pGL-Luc was injected i.t. and TUS was applied, luciferase expression in the harvested tumors was 3.1 Â 10 3 70.6 Â 10 3 RLU/mg protein (Figure 3a ). This expression was significantly higher (Po0.001) than the one obtained in tumors in which the DNA was injected s.c. (o300 RLU/mg protein). Moreover, when the plasmid was injected s.c. and TUS was applied, luciferase expression was detected in the skin (1.4 Â 10 3 70.2 Â 10 3 RLU/mg protein), but was hardly detected in the tumors (o500 RLU/mg protein). In both administration sites, no expression was detected in the liver (o50 RLU/mg protein, Figure 3a) . In tumors treated with DNA alone, without TUS, luciferase activity was less than 40 RLU/mg protein regardless of the injection site (Figure 3b) .
In vivo optimization of transfection with Optison using TUS To optimize the effect of Optison on in vivo transfection using TUS, DNA-Optison was injected i.t. (Figure 3a) as No significant increase in gene expression in vivo was detected when TUS was applied for 30 min compared with 20 min (Figure 3b, inset) . However, temperature measurements of the tumor and the skin during TUS application revealed that when applying TUS for 20 min the maximum temperature increase was less than 31C. Whereas applying TUS for 30 min resulted in a slightly higher temperature. Therefore, for the rest of the in vivo studies, TUS was applied for 20 min.
In vivo optimization of protein distribution in the tumor
To study the expression and the efficiency of DNA transfection in tumors and the effect of Optison on this distribution in vivo, pGFP alone or pre-incubated with Optison was injected s.c. or i.t. and TUS of 1 MHz, 30% DC at 2 W/cm 2 was then applied for 20 min (Figure 4 ). Sections of tumors revealed that when the plasmid was injected s.c. and TUS was applied, most of the GFP expression was observed at the outer vicinity of the tumor. Moreover, the inner side of the skin near the tumor also expressed GFP (Figure 4a) . Incubation of the plasmid with Optison before s.c. injection and TUS application resulted in a slight increase in tumor and skin area expressing GFP (Figure 4a ). Quantification of transfection efficiency, that is the percent of cells expressing GFP per field, revealed that both the skin and the tumor express GFP almost in the same level. When using Optison the increase in GFP expression was insignificant compared with treatments with TUS alone (Figure 4b) . Injection of pGFP IT followed by TUS application resulted in GFP expression that was more condensed and located at one area of the tumor (Figure 4c ). Almost no GFP expression was seen in the skin around the tumor. When Optison and DNA were pre-incubated, injected i.t., and TUS was applied, tumor area expressing GFP was elevated, and GFP was better distributed throughout the tumor (Figure 4c ). Quantification using image analyses indicated that almost all of the GFP expression was located in the tumor, and the addition of Optison significantly increased the transfection efficiency (Figure 4d ).
Kinetics of pDNA expression in vivo
The kinetic of pDNA expression in vivo was determined using pGL-Luc. Tumors were injected IT with pGL-LucOptison and treated with TUS. Tumors, skin and livers were harvested 3, 7 and 14 days post-TUS application (Figure 5a and b) . As seen from Figure 5 (a), a decrease in almost two fold in tumor luciferase activity was detected 7 days post-TUS. At 14 days post-TUS, luciferase activity was further decreased by almost four fold. When analyzing the skin and the liver, almost no luciferase activity were detected even at 3 days post-TUS application. RT-PCR analyses for the luciferase gene performed on tumors 3, 7 and 14 days post-TUS further supported these results (Figure 5b) . In some mice, luciferase RNA was hardly detected 14 days post-TUS application, suggesting that its degradation is faster than the protein itself.
Kinetics of protein distribution and transfection efficiency in vivo
Using pGFP, the kinetics of DNA distribution and transfection efficiency in the tumors, skin and livers were As with luciferase, a marked decrease in transfection efficiency was observed 7 and 14 days, compared with 3 days post-TUS application. This decrease was less than the one observed with luciferase: B1.5-fold at 7 days and B3-fold at 14 days post-TUS application, reaching 873% compared with 22%75 at 3 days post-TUS. Yet, at 3 days post-TUS application there is a large area in the tumor expressing GFP. At 7 days post-TUS, a decrease in the area expresses GFP was observed, but still GFP expression was distributed in the tumor. At 14 days post-TUS, the expression of GFP was observed in smaller and separated tumor areas. Nevertheless, these locations were distributed throughout the tumor, indication for high-transfection efficiency. Some level of GFP expression (o6%) was observed in the skin around the tumor 3 days post-TUS, but almost no expression was detected at 7 and 14 days post-TUS. No expression was observed in the liver of the mice in any time point (Figure 5d ).
Histology observation post-TUS application
Histology analyses performed by H&E staining shows that the exposure of the tumors to TUS application at 2 W/cm 2 , 30% DC, for 20 min does not damage the tumor tissue, leaving it intact and without infection (Figure 6a) . Moreover, the skin around the tumor (not shown) and the liver possessed normal histology (Figure 6b ).
Discussion
The gene therapy field is constantly progressing from the experimental setting to the clinical bench. Nevertheless, the main stumbling block remains the methods or vectors for delivering the DNA to the tissue and organ. The present study focuses on the in vivo optimization of TUS, which is considered as one of the promising non-viral methods to be approved for clinical studies. To properly control TUS application in vivo, TUS parameters need to be optimized first in vitro and then implemented in vivo, although this is not so straightforward. 29 From the present in vitro studies it is evident that TUS operated at 30% DC, 2 W/cm 2 for 30 min result in the highest gene expression in PC2 cells, while maintaining high cell viability. This level of expression increases by two fold when pDNA is pre-incubated with Optison and then subjected to TUS application. The level of expression is also significantly higher compared to other non-viral method, such as Lipofectamine.
Based on the results obtained in vitro, in vivo studies were designed in which TUS of 2 W/cm 2 , 30% DC was applied for 20 or 30 min. Applying TUS in vivo for long time periods (more than 15 min) was not attempted before, and may increase tissue temperature as opposed to the in vitro conditions. The in vivo studies demonstrate that increasing TUS exposure time from 20 to 30 min did not increase gene expression significantly (as in the in vitro Long-term TUS for tumor transfection M Duvshani-Eshet and M Machluf studies), but increased the temperature in the tissue. Therefore, for the rest of the in vivo studies, TUS was applied for 20 min.
Another important parameter, which needs to be addressed in vivo and is absent in vitro, is the route of DNA administration before TUS application. Once Long-term TUS for tumor transfection M Duvshani-Eshet and M Machluf determining the best route of DNA administration, the other parameters such as expression level and efficiency and the effect of USCA may be compared.
In the first set of experiments, the effect of the route of DNA administration on gene expression level post-TUS was evaluated. The studies indicated that i.t. administration is superior to the s.c. administration. Nevertheless, it appears that expression level in vivo was lower than the one obtained in vitro using the same TUS parameters with both plasmids: luciferase or GFP. One possible explanation is the availability of the DNA to the cells during the transfection process. Kawase et al. 2 have found that when pDNA is injected in vivo (intratumoral or intramuscular), some of the DNA is washed with the blood flow, suggesting that increase in transfection may be achieved by increasing the amount of DNA. The amount of DNA used for the present in vivo studies (100 mg) was already higher than the amount of DNA used in vitro (30 mg). Another possible explanation is the difference in the exposure of the cells to the TUS waves. In vitro, all the cells are exposed to the TUS wave as they are cultured as monolayer. On the other hand, in vivo, not all the cells in the tumor are exposed to the TUS in the same level owing to the three-dimensional structure of the tissue and the depth of TUS wave penetration. 29, 30 A third possible explanation involves the ability of TUS to create cavitation in vivo. It is suggested that cavitation is less likely to occur in vivo, particularly in the dense tissue of the tumor, where there is less space available for bubbles to oscillate 31 and also when using frequencies in the therapeutic range (X1 MHz). 8, 18, 32 Therefore, increase in the expression, in vivo, may be achieved by using USCA that lowers the threshold for cavitation. The effect of USCA on gene expression in vivo post-TUS was addressed by using Optison, a third generation of USCA. The Optison micro-bubbles compris of perfluoropropane gas stabilized in heat-denatured albumin shell and are approved for echocardiography. 33 The optimal conditions to be used when Optison, DNA and long-term TUS used in vivo, particularly in tumors, are not reported. Thus, several concerns need to be addressed before using this combinatorial system: The preferred route of DNAOptison administration, the effect of long-term TUS with Optison on spatial distribution and transfection efficiency in tumors and the effect of long-term TUS with Optison on the duration of protein expression.
As discussed earlier, i.t. administration is preferable to the s.c. in terms of gene expression and protein distribution in the tumors. When using i.t. administration, most of the expression is by the tumor cells rather than adjacent tissue like the skin. Yet, as the tumor tissue is very dense, we theorized that injection of Optison i.t. will be difficult, and even if this could be achieved, Optison might not be able to oscillate and induce cavitation. The results from this study show that the gene expression was significantly increased when DNA was injected i.t. with Optison compared with the s.c. injection, and to DNA alone using both routes. Moreover, the use of pGFP revealed that pre-incubation of the DNA with Optison before i.t. injection and TUS application resulted in higher efficiency and better distribution of the expressed GFP in the tumor when compared with DNA alone. The pattern of GFP expression post DNA-Optison injection, which was not limited to the site of injection and was not evenly distributed suggests the involvement of cavitation. 23 It is possible that i.t. injection of Optison may result with micro-injury in the tumor, which then provides 'space' for bubbles, oscillation and the creation of cavitation in the tumor that eventually lead to plasmid distribution and higher transfection efficiency, as was also suggested by Miller and Song. 12 This result implies that even in the dense tissue of the tumor, injection of Optison before long-term TUS application for 20 min, may result in cavitation. Our previous in vitro studies with Optison suggested that applying TUS for more than 15 min not only results in bubbles oscillation, but also induces cavitation. 20 Thus, it is possible that the application of TUS for 20 min or more is necessary for Optison to oscillate in the tumor resulting in much higher transfection efficiency and protein expression in the tumor.
Although our in vivo results are in agreement with most of the other studies using US for cancer gene delivery, 9,12,13 a major difference appears to be the mode of US used. Most of the studies applying US for cancer gene therapy have used HIFU and not TUS. Huber et al. 9 reported that injection of Optison together with DNA, i.v., reduces significantly the availability of the plasmid to the tumor and, therefore, the transfection in the tumor was very low compared with i.t. injection. 9 Miller and Song 12 injected the plasmid i.t. and Optison either i.t. or i.v. and found that, when Optison was injected i.t., a further increase in transfection was observed. Manome et al. 13 also used HIFU for gene delivery into tumors in vivo and found the transfection to be localized in the tumor, but, they did not use USCA. Although HIFU can penetrate into deeper areas in the body, the application of HIFU involves much higher intensities (10-50 W/cm 2 ) that may damage the tissue by both lyses of the cells 12 and by increase in tissue temperature. 34 Therefore, HIFU is mostly used in ablation of tissues, such as tumors. 35, 36 The intensities applied by TUS are much lower (0.5-3 W/cm 2 ) suggesting less damage to the surrounding tissues and thus broader use for tissue and organ application. The histology studies of sections taken from tumors of skin and livers revealed that no inflammatory or wounds were observed and no redness or burning of the skin were seen when TUS was applied at 2 W/cm 2 , 30%DC for 20 min, even with the addition of Optison. Other studies, which applied TUS and not HIFU, have used different routes of DNA administration and different US parameters, particularly exposure times of less than 15 min. 10, 26, 37 Sakakima et al. 37 have used, in vitro, a 1 MHz, 0.5 W/cm 2 30%DC for 30 s. However, for the in vivo studies, they applied 2 W/cm 2 , 50% DC for 10 min to tumor injected i.t. with DNA. No evaluation of the duration of protein expression or effect of the route of injection was made, and no explanation for the in vivo choice of TUS parameters was given.
Lastly, we have determined the duration of protein expression in the tumors and compared it with the in vitro Long-term TUS for tumor transfection M Duvshani-Eshet and M Machluf one. Using the two plasmids coding for luciferase and GFP, our data show a decrease in expression level and efficiency 7 and 14 days post-TUS application. The decrease in luciferase activity was greater than the decrease in GFP expression, which may be due to the normalization of RLU by milligrams protein in the tumor that continues to grow 7 and 14 days post-TUS application. Nevertheless, RT-PCR of the luciferase gene revealed that there are tumor cells transcribing the mRNA even at 14 days post-treatment. These results are in agreement with other studies which used TUS of 1 MHz with USCA to deliver genes to tumors, 10 kidney 34 or vasculature. 38 In summary, the observations from this study support the general hypothesis that transfection in tumors can be efficiently achieved using long-term TUS application with Optison. Most importantly, this study implies that the long-term application of TUS can be used for the localization of gene in tumors. The decrease in gene expression suggests that this technology is more suitable for short-term expression, whereas for longer durations repeated treatments may be needed. As naked DNA is not immunogenic, and TUS at relatively low intensity does not damage the tissue, repeated application of TUS even for long time periods is of no concern and may be advantageous. Based on this study, we are currently applying long-term TUS-Optison for the therapeutic treatment of prostate tumors.
